The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Evorpacept, lenalidomide and rituximab for high tumor burden indolent B-NHL: a Phase II trial
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a Phase II investigator-initiated frontline trial (NCT05025800) of evorpacept, lenalidomide and rituximab for high tumor burden indolent B-cell non-Hodgkin lymphoma (B-NHL). Dr Strati highlights that the combination has shown promising efficacy, and notes that further follow-up is needed to determine if this treatment translates into durable remissions. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
